Amylyx Pharmaceuticals is now a one-asset, one-quarter story, and the calendar is about to answer the question that has defined the equity since the company pivoted away from the failed RELYVRIO franchise. The pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia has just completed its last patient visit in the double-blind period, and management is guiding to a topline readout in late August or early September of this year, a window that begins in roughly two weeks. The most recent quarterly print was the calm before that storm: a $43.4 million net loss on $45.7 million of operating expenses, with $250.8 million in cash and marketable securities confirming a runway into 2028 and leaving the equity to focus on the trial data rather than the income statement. With a market capitalization of approximately $2.4 billion on 111.4 million shares outstanding at the August 14 close of $21.63, the equity is pricing a binary clinical event with a thin buffer of capital, a pre-commercialization spend ramp, and a $6.5 million legal settlement that became preliminarily approved in May.
The thesis has three moving parts. First, a positive LUCIDITY readout would unlock an FDA approval path in a disease with no approved therapy, the first-in-class GLP-1 receptor antagonist designation Amylyx already holds, a 2027 commercial launch, and a clean run at a patient population of approximately 160,000 U.S. adults who underwent sleeve gastrectomy or Roux-en-Y gastric bypass, a number that has not been validated but is supported by clinical literature. Second, a negative or ambiguous readout would compress the equity toward the value of the cash, the AVXL-035, or AMX0318, long-acting GLP-1 antagonist option, and the AMX0114 ALS antisense oligonucleotide option, none of which are independently worth a $2.4 billion market capitalization today. Third, the runway into 2028 buys management time to either execute the launch or restructure the company around the data, but the runway is not free. The pre-commercialization build is showing up in the SG&A line, which climbed 40% year over year to $21.9 million in Q2, and the avexitide-specific R&D line is also rising as the company funds NDA, which stands for New Drug Application, readiness. If the launch slips by a year, the runway compresses to a single quarter, and Amylyx is back in the capital markets.
The single load-bearing risk is a Phase 3 readout that misses the FDA-agreed-upon primary endpoint of reduction in the composite of Level 2 and Level 3 hypoglycemic events, where Level 2 is blood glucose below 54 milligrams per deciliter and Level 3 is severe cognitive impairment requiring external assistance, through Week 16. The Phase 2 PREVENT data showed a 21% to 26% increase in mean plasma glucose nadir, a reading of the lowest blood glucose level after a meal, and the Phase 2b showed 53% to 66% reductions in Level 2 and Level 3 event rates. The dose, the 90 mg once-daily subcutaneous regimen, is the same in LUCIDITY as in the Phase 2b, and management has flagged that the last patient visit just completed, which removes a known overhang on the timeline. The single most important data point between now and year-end is the topline press release; the second is the FDA submission timing; the third is the launch uptake curve, which we read as the load-bearing set of price catalysts for the equity.